Ulrik Nielsen
Fondateur chez MERRIMACK PHARMACEUTICALS, INC.
Fortune : 544 539 $ au 30/04/2024
Postes actifs de Ulrik Nielsen
Sociétés | Poste | Début | Fin |
---|---|---|---|
MERRIMACK PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 30/01/2015 | - |
Fondateur | 01/01/1993 | - | |
Independent Dir/Board Member | 30/01/2015 | - | |
Directeur Technique/Scientifique/R&D | 01/01/1993 | 30/01/2015 | |
Tidal Therapeutics, Inc.
Tidal Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sanofi, Tidal Therapeutics, Inc. is a preclinical biotech company based in Quincy, MA. Tidal Therapeutics, Inc. focuses on developing nanoparticles that deliver to reprogram immune cells inside the body, with applications in oncology and immune diseases. Ulrik B. Nielsen has been the CEO of the company since 2018. Tidal Therapeutics was acquired by Sanofi on April 09, 2021 for $470 million. | Directeur/Membre du Conseil | 01/08/2018 | - |
Directeur Général | 01/08/2018 | - | |
President | 01/08/2018 | - | |
Treasurer | 01/08/2018 | - | |
Alloy Therapeutics LLC
Alloy Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Alloy Therapeutics LLC is a biotechnology ecosystem company that democratizes access to tools, technologies, services, and company creation capabilities for discovering and developing therapeutic biologics. The company's lead offering is the ATX-GX™ platform, a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Through a community of partners across academia, biotech, and the largest biopharma, Alloy is a leader in bispecific antibody discovery and engineering services, utilizing its proprietary ATX-CLC common light chain platform integrating novel transgenic mice and phage display. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Hanover, NH, with European labs in Switzerland. The company was founded by Errik B. Anderson, who has been the CEO since incorporation. | Directeur/Membre du Conseil | 01/01/2019 | - |
Historique de carrière de Ulrik Nielsen
Anciens postes connus de Ulrik Nielsen
Sociétés | Poste | Début | Fin |
---|---|---|---|
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | Directeur Général | 01/01/2015 | 14/11/2017 |
Président | 14/11/2017 | 01/06/2018 | |
Fondateur | 01/01/2015 | 01/06/2018 | |
President | 01/01/2015 | 01/06/2018 | |
Silver Creek Pharmaceuticals, Inc.
Silver Creek Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Silver Creek Pharmaceuticals, Inc. develops novel regenerative medicines. The firm focuses on treating cardiovascular disease. Its molecules are designed to promote resilience and regeneration of damaged tissues after acute or chronic injury. The company was founded in 2010 and is headquartered in San Francisco, CA. | Directeur Général | 01/07/2010 | 01/03/2014 |
Notch Therapeutics, Inc.
Notch Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Notch Therapeutics, Inc. engages in the development of cell therapies for the treatment of diseases. It offers technology platform, which uses genetically tailored stem cells as a renewable source for creating allogeneic T cell therapies that expand treatment options and deliver cell immunotherapies to patients. The company was founded by Juan Carlos Zuniga-Pflucker and Peter Zandstra in 2018 and is headquartered in Toronto, Canada. | Directeur Général | - | 20/07/2020 |
Président | - | - |
Formation de Ulrik Nielsen
University of Copenhagen | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 6 |
Danemark | 2 |
Canada | 2 |
Opérationnelle
Chief Executive Officer | 4 |
Director/Board Member | 3 |
Founder | 2 |
Sectorielle
Health Technology | 5 |
Commercial Services | 3 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
MERRIMACK PHARMACEUTICALS, INC. | Health Technology |
Entreprise privées | 5 |
---|---|
Silver Creek Pharmaceuticals, Inc.
Silver Creek Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Silver Creek Pharmaceuticals, Inc. develops novel regenerative medicines. The firm focuses on treating cardiovascular disease. Its molecules are designed to promote resilience and regeneration of damaged tissues after acute or chronic injury. The company was founded in 2010 and is headquartered in San Francisco, CA. | Health Technology |
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | Health Technology |
Notch Therapeutics, Inc.
Notch Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Notch Therapeutics, Inc. engages in the development of cell therapies for the treatment of diseases. It offers technology platform, which uses genetically tailored stem cells as a renewable source for creating allogeneic T cell therapies that expand treatment options and deliver cell immunotherapies to patients. The company was founded by Juan Carlos Zuniga-Pflucker and Peter Zandstra in 2018 and is headquartered in Toronto, Canada. | Health Technology |
Tidal Therapeutics, Inc.
Tidal Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sanofi, Tidal Therapeutics, Inc. is a preclinical biotech company based in Quincy, MA. Tidal Therapeutics, Inc. focuses on developing nanoparticles that deliver to reprogram immune cells inside the body, with applications in oncology and immune diseases. Ulrik B. Nielsen has been the CEO of the company since 2018. Tidal Therapeutics was acquired by Sanofi on April 09, 2021 for $470 million. | Commercial Services |
Alloy Therapeutics LLC
Alloy Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Alloy Therapeutics LLC is a biotechnology ecosystem company that democratizes access to tools, technologies, services, and company creation capabilities for discovering and developing therapeutic biologics. The company's lead offering is the ATX-GX™ platform, a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Through a community of partners across academia, biotech, and the largest biopharma, Alloy is a leader in bispecific antibody discovery and engineering services, utilizing its proprietary ATX-CLC common light chain platform integrating novel transgenic mice and phage display. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Hanover, NH, with European labs in Switzerland. The company was founded by Errik B. Anderson, who has been the CEO since incorporation. | Commercial Services |
- Bourse
- Insiders
- Ulrik Nielsen
- Expérience